TY - JOUR T1 - A deductive approach to modeling the spread of COVID-19 JF - medRxiv DO - 10.1101/2020.03.26.20044651 SP - 2020.03.26.20044651 AU - Pranav Mishra AU - Shekhar Mishra Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/03/30/2020.03.26.20044651.abstract N2 - Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), previously known as 2019-nCoV, is responsible for the atypical pneumonia pandemic designated as Coronavirus Disease 2019 (COVID-19). The number of cases continues to grow exponentially reaching 492,000 people in 175 countries as of March 25, 2020. 22,169 people (∼4.5%) infected with SARS-COV-2 virus have died. We have developed an exponential regression model using the COVID-19 case data (Jan 22 – Mar 22, 2020). Our primary model uses designated Phase 1 countries, who exceed 2500 cases on Mar 22. The model is then applied to Phase 2 countries: those that escaped the initial Phase 1 global expansion of COVID-19. With the exception of stabilizing countries (South Korea, Japan, and Iran) all Phase 1 countries are growing exponentially, as per I2500(t) = 120.4 × e0.238t, with a rate, r = 0.238 ± 0.068. Excluding China, the BRICS developing nations and Australia are in Phase 2. Case data from Phase 2 countries are following the model derived from Phase 1 countries. In the absence of measures employed to flatten the curve including social distancing, quarantine, and healthcare expansion, our model projects over 274,000 cases and 12,300 deaths in the US by Mar 31. India can expect 123,000 cases by April 16. By flattening the curve to the growth rate of stabilizing countries (r = 0.044 ± 0.062), the US would prevent 8,500 deaths by Mar 31, and India would prevent 5,500 deaths by April 16.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was received or required for this studyAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesOur study examines this pandemic through data provided by the Johns Hopkins University’s Systems Science and Engineering Group (JHU CSSE. It is an aggregation of case data starting on January 22, 2020 CSSEGISandData. 2019 Novel Coronavirus COVID-19 (2019-NCoV) Data Repository by Johns Hopkins CSSE. Johns Hopkins University Center for Systems Science and Engineering; 2020. https://github.com/CSSEGISandData/COVID-19. Accessed March 23, 2020. https://github.com/CSSEGISandData/COVID-19 ER -